title: High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.
abstract: METHODS
  Prospective cohort study.
  
  
  OBJECTIVE
  Although Bracken et al have demonstrated a significant neuroprotective effect of high-dose intravenous (i.v.) methylprednisolone (MP) within 8 h post spinal cord injury (SCI), this practice has recently been challenged. We hypothesized it is possible that acute corticosteroid myopathy (ACM) may occur secondary to the MP. This pilot study was performed to test this hypothesis.
  
  
  METHODS
  University of Miami School of Medicine/Jackson Memorial Hospital, Miami VA Medical Center, FL, USA.
  
  
  METHODS
  Subjects included five nonpenetrating traumatic SCI patients, who received 24 h MP according to National Acute Spinal Cord Injury Studies (NASCIS) protocol, and three traumatic patients who suffered SCI and did not receive MP. Muscle biopsies and electromyography (EMG) were performed to determine if myopathic changes existed in these patients.
  
  
  RESULTS
  Muscle biopsies from the SCI patients who received 24 h of MP showed muscle damage consistent with ACM in four out of five cases. EMG studies demonstrated myopathic changes in the MP-treated patients. In the three patients who had SCI but did not receive MP, muscle biopsies were normal and EMGs did not reveal evidence of myopathy.
  
  
  CONCLUSIONS
  Our data suggest that MP in the dose recommended by the NASCIS may cause ACM. If this is true, part of the improvement of neurological recovery showed in NASCIS may be only a recording of the natural recovery of ACM, instead of any protection that MP offers to the injured spinal cord.
authors.affiliation: Department of Physical Medicine & Rehabilitation, University of Miami School of Medicine, FL 33125, USA.
authors.forename: T
authors.initials: T
authors.lastname: Qian
authors.forename: X
authors.initials: X
authors.lastname: Guo
authors.forename: A D
authors.initials: AD
authors.lastname: Levi
authors.forename: S
authors.initials: S
authors.lastname: Vanni
authors.forename: R T
authors.initials: RT
authors.lastname: Shebert
authors.forename: M L
authors.initials: ML
authors.lastname: Sipski
mesh_terms: D000251:Adenosine Triphosphatases / Q000378:metabolism; D000328:Adult; D000368:Aged; D001706:Biopsy / Q000379:methods; D004576:Electromyography / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects*; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D009135:Muscular Diseases / Q000209:etiology* / Q000473:pathology; D009431:Neural Conduction / Q000187:drug effects; D018696:Neuroprotective Agents / Q000009:adverse effects*; D011446:Prospective Studies; D013119:Spinal Cord Injuries / Q000188:drug therapy / Q000473:pathology; D013194:Staining and Labeling / Q000379:methods; D013997:Time Factors
chemical_list: D018696:Neuroprotective Agents; D000251:Adenosine Triphosphatases; D008775:Methylprednisolone